COMUNICADO: Positive European Commission Decision on flutiform® (fluticasone propionate/formoterol fumarate), a New Combination Ther

Actualizado 03/07/2012 16:37:43 CET


- is more effective in improving asthma symptom scores, including an
improvement in the percentage of symptom-free days and awakening-free nights, compared
with a similar dose of fluticasone alone[4]
- provides similar improvements in lung function parameters, control of asthma
symptoms and similar level of exacerbations compared to its individual components
administered concurrently via separate inhalers[4]
- has a more rapid onset of bronchodilatory action than the
fluticasone/salmeterol combination as defined by the first time point post-dose at
which FEV1 was at least 12 percent greater than the pre-dose value. The superiority of

fluticasone/formoterol combination (100/10 or 250/10 mug b.i.d.) compared to the
fluticasone/salmeterol combination (100/50 or 250/50 mug b.i.d.) was shown over a
12-week study period (HR 1.64)[3]
- has a safety and tolerability profile similar to that of its individual
components administered concurrently via separate inhalers[4]

About Mundipharma

Mundipharma International provides fully integrated support across multiple disciplines for a network of independent pharmaceutical companies across Europe. The Mundipharma independent associated companies have become leaders in pain management, and are building a growing presence in the oncology, rheumatoid arthritis and respiratory markets. Through innovation and acquisition, the Mundipharma mission is to deliver cutting-edge treatment solutions that meet the pressing needs of healthcare professionals and patients. For more information: http://www.mundipharma.com

(R) denotes a registered trade mark

References

1. flutiform SmPC

2. Bodzenta-Lukaszyk A, R Buhl, et al. Eur Respir J 2011a;38:153s

3. Bodzenta-Lukaszyk A, Dymek A et al. BMC Pulm Med J. 2011;11:28

4. Bodzenta-Lukaszyk A, Pulka et al. Respir Med J. 2011;105(5):674-82

CONTACT: For further information please contact: Lara Dow, Head ofEuropean Communications and Congress, Lara.Dow@mundipharma.co.uk, 3 Jul. (0) - 1223-397-674; Lisa Henry, lhenry@websershandwick.com,+44(0)2070-670-0808

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación